Eli Lilly and Company $LLY is Dana Investment Advisors Inc.'s 10th Largest Position

Key Points

• Dana Investment Advisors reduced its Eli Lilly stake by 5.7% in the fourth quarter, but LLY still remains its 10th-largest holding, worth about $44.1 million.
• Eli Lilly reported a strong quarter, with EPS of $8.55 versus $6.97 expected and revenue of $19.8 billion versus $17.82 billion expected, while quarterly revenue jumped 55.5% year over year.
• Analyst sentiment remains bullish overall: several firms raised targets or reiterated buy ratings, and the stock currently carries a Moderate Buy consensus with an average price target of $1,218.33.

Dana Investment Advisors Inc. cut its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 5.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 41,033 shares of the company's stock after selling 2,481 shares during the quarter. Eli Lilly and Company makes up 1.3% of Dana Investment Advisors Inc.'s investment portfolio, making the stock its 10th largest holding. Dana Investment Advisors Inc.'s holdings in Eli Lilly and Company were worth $44,098,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Hills Bank & Trust Co increased its holdings in Eli Lilly and Company by 6.6% in the 4th quarter. Hills Bank & Trust Co now owns 3,177 shares of the company's stock worth $3,414,000 after acquiring an additional 196 shares during the last quarter. Lawood & Co. bought a new stake in Eli Lilly and Company in the 4th quarter valued at about $551,000. S&CO Inc. raised its stake in Eli Lilly and Company by 0.9% in the 4th quarter. S&CO Inc. now owns 20,209 shares of the company's stock valued at $21,718,000 after acquiring an additional 181 shares during the period. Financial Security Advisor Inc. raised its stake in Eli Lilly and Company by 8.0% in the 4th quarter. Financial Security Advisor Inc. now owns 4,339 shares of the company's stock valued at $4,663,000 after acquiring an additional 322 shares during the period. Finally, Novare Capital Management LLC raised its stake in Eli Lilly and Company by 24.0% in the 4th quarter. Novare Capital Management LLC now owns 5,116 shares of the company's stock valued at $5,498,000 after acquiring an additional 989 shares during the period. Institutional investors own 82.53% of the company's stock.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. UBS Group restated a "buy" rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Weiss Ratings upgraded Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research note on Monday, May 4th. Cantor Fitzgerald boosted their price objective on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the company an "overweight" rating in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 6th. Finally, Daiwa Securities Group raised their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a "buy" rating in a research note on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,218.33.

Eli Lilly and Company Stock Down 0.1%

LLY stock opened at $1,005.20 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a market capitalization of $946.63 billion, a PE ratio of 35.71, a PEG ratio of 1.10 and a beta of 0.48. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,133.95. The stock has a 50-day simple moving average of $939.88 and a two-hundred day simple moving average of $997.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company's quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company's payout ratio is presently 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Erste Group raised its FY2026 EPS estimate for Eli Lilly, lifting its forecast to $36.30 per share from $36.06 and above the broader consensus of $35.80, signaling continued earnings momentum.
• Positive Sentiment: Guggenheim recently boosted Lilly’s price target by $52 after the company’s strong first-quarter results, reinforcing the view that analysts see more upside after another blowout quarter.
• Positive Sentiment: Media coverage continues to highlight Lilly as one of the most watched stocks, with commentary pointing to its dominant position in the weight-loss drug market and ongoing bullish investor interest. Article: Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Positive Sentiment: Several reports pointed to Lilly’s expanding pipeline, including new and advancing trials in ALS, GI disease, and immuno-dermatology, which adds optionality beyond its core diabetes and obesity franchises.
• Positive Sentiment: Investor sentiment also got a boost from headlines calling Lilly a potential bull-market leader and suggesting the stock could approach $1,100 if momentum continues. Article: Is Eli Lilly Going To $1,100?
• Neutral Sentiment: Lilly and UNICEF announced a $50 million partnership tied to the company’s 150th anniversary, which may help its ESG profile and public image, but the direct earnings impact appears limited in the near term.
• Neutral Sentiment: Some articles were mainly awareness pieces or broad market commentary rather than company-specific catalysts, so they are unlikely to be major stock drivers on their own.
• Negative Sentiment: Broader market commentary warned that the S&P 500 may be due for a correction, which could create short-term pressure on high-multiple growth stocks like Lilly if risk appetite fades.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.